New hope for tough-to-treat pancreatic cancer patients with specific genetic mutation

NCT ID NCT06008288

Recruiting now Disease control Sponsor: Allist Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing an experimental drug called Glecirasib for people with advanced pancreatic cancer and other solid tumors that have a specific genetic change called KRAS G12C. The trial is for patients whose cancer has continued to grow despite previous standard treatments. Researchers want to see if this targeted therapy can shrink tumors and control the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Anhui Provincial Cancer Hospital
RECRUITING

Hefei, Anhui, China
Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Beijing Tsinghua Changgung Hospital
RECRUITING

Beijing, Beijing Municipality, China
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, China
Guangxi Medical University Cancer Hospital
RECRUITING

Nanning, Guangxi, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, China
Huashan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, China
Hubei Cancer Hospital
RECRUITING

Wuhan, Hubei, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, China
Hunan Provincial People's Hospital
RECRUITING

Changsha, Hunan, China
Jiangsu Cancer Hospital
RECRUITING

Nanjing, Jiangsu, China
Jiangsu Province Hospital
RECRUITING

Nanjing, Jiangsu, China
Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China
Shandong Cancer Hospital
RECRUITING

Jinan, Shandong, China
Shanghai Changhai Hospital
RECRUITING

Shanghai, Shanghai Municipality, China
Sun Yat-Sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, China
The Affiliated Hospital of Qingdao University
NOT_YET_RECRUITING

Qingdao, Shandong, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, China
The First Affiliated Hospital of Sun, Yat-sen University
RECRUITING

Guangzhou, Guangdong, China
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITING

Xi’an, Shanxi, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, China
The First Affiliated Hospital, Zhejiang University School of Medicine
NOT_YET_RECRUITING

Hangzhou, Zhejiang, China
The First Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, China
Tianjin Medical University Cancer Institute＆Hospital
RECRUITING

Tianjin, Tianjin Municipality, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China
West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital
RECRUITING

Hangzhou, Zhejiang, China

Conditions

Explore the condition pages connected to this study.

KRAS P.G12C PANCREATIC CANCER SOLID TUMOR